Dr. Bihari, by 2003, had been treating 350 AIDS patients using LDN in conjunction with accepted AIDS therapies. During 7 years of treatments,between 1996 and 2003, over 85% of his patients showed no detectable levels of the HIV virus — a much higher success ratethan most current AIDS treatments, and with no significant side effects.
It is also worth noting that many HIV/AIDS patients have been living symptom-free for years, while taking only LDN with no other medications.
Two studies in the African country of Mali, demonstrated LDN’s successful use in HIV/AIDS, as published in October, 2011 in the Journal of AIDS and HIV Research.
================
TNI BioTech Inc
Symbol: TNIB
Price: $1.25
=================
Biotechs Poised For Big Gains In 2012!
Additionally, in the mid-1990s, Dr. Bihari found that patients in his practice with cancer, such as lymphoma or pancreatic cancer, also benefited from LDN. People with autoimmune diseases, such as lupus, also often showed prompt control of disease activity while taking LDN.
There have been a number of Phase I and Phase II trials involving the use of LDN and it is important now for TNI BioTech, Inc. to complete the work of Dr. Bernard Bihari and others. The company believes, with the acquisition of the portfolio, it will be able to move forward with Phase III trials involving LDN, which will be marketed under the trade name IRT-103.
Dr. Nicholas Plotnikoff, Chairman of TNI BioTech, Inc., states, “I worked with Dr. Bernard Bihari for many years and I believe acquiring all of the technology of Dr. Bihari will allow the company, we hope, to move forward to phase III clinical trials in both the United States and Africa within the next 12 months. In our opinion, LDN holds great promise for the millions of people worldwide with autoimmune diseases or central nervous system disorders or who face a deadly cancer. It could prove to be the first low-cost, easy to administer, and side-effect-free therapy for Cancer, HIV/AIDS, MS and Crohn’s disease.”
“The Opportunity’s Coming… Are You Ready?”
It’s no secret that the biotech sector is potentially setting itself up to deliver huge gains in the months ahead.
*Titan Pharmaceuticals (TTNP) jumped 11,900% in 10 months…
*Genitope (GTOP) rocketed 1,455% in just 10 days!
*Cell Therapeutics (CTIC) soared 4,360% in less than 3 months!
*Keryx Biopharma (KERX) gained 3,733% over 9 months…
*Vanda Pharmaceuticals (VNDA) advanced 3,314% in 7 months…
“The Money’s Coming… Are You Ready To Grab Your Share?”
About TNI Biotech, Inc.
TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body’s immune system using our patented immunotherapy.
Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient’s lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient’s lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.
However, even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:
– Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
– As an adjunct to antibiotics in the treatment of infectious diseases;
– In cancer patients undergoing chemotherapy, radiation treatments or surgery;
– Patients with AIDS, in combination with retroviral drug therapy; and
– In wound healing or herpes viral infections.
